Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
The closing price of Taysha Gene Therapies Inc (NASDAQ: TSHA) was $5.26 for the day, up 7.57% from the previous closing price of $4.89. In other words, the price has increased by $7.57 from its previous closing price. On the day, 3.77 million shares were traded. TSHA stock price reached its highest trading level at $5.3 during the session, while it also had its lowest trading level at $4.8.
Ratios:
Our analysis of TSHA’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 10.47 and its Current Ratio is at 10.47. In the meantime, Its Debt-to-Equity ratio is 0.32 whereas as Long-Term Debt/Eq ratio is at 0.31.
Upgrades & Downgrades
In the most recent recommendation for this company, Raymond James on October 21, 2025, initiated with a Strong Buy rating and assigned the stock a target price of $13.
On July 11, 2025, BofA Securities started tracking the stock assigning a Buy rating and target price of $8.
On June 27, 2024, BMO Capital Markets started tracking the stock assigning a Outperform rating and target price of $5.BMO Capital Markets initiated its Outperform rating on June 27, 2024, with a $5 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Dec 01 ’25 when Nagendran Sukumar sold 260,047 shares for $4.51 per share. The transaction valued at 1,172,812 led to the insider holds 1,006,439 shares of the business.
Nagendran Sukumar sold 110,125 shares of TSHA for $523,094 on Nov 28 ’25. The President and Head of R&D now owns 1,006,439 shares after completing the transaction at $4.75 per share. On Nov 28 ’25, another insider, Nagendran Sukumar, who serves as the Officer of the company, bought 370,172 shares for $4.86 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TSHA now has a Market Capitalization of 1440815872 and an Enterprise Value of 1212554880. For the stock, the TTM Price-to-Sale (P/S) ratio is 228.34 while its Price-to-Book (P/B) ratio in mrq is 6.58. Its current Enterprise Value per Revenue stands at 192.164 whereas that against EBITDA is -12.008.
Stock Price History:
The Beta on a monthly basis for TSHA is 0.99, which has changed by 1.5336788 over the last 52 weeks, in comparison to a change of 0.16623151 over the same period for the S&P500. Over the past 52 weeks, TSHA has reached a high of $6.02, while it has fallen to a 52-week low of $1.05. The 50-Day Moving Average of the stock is 7.70%, while the 200-Day Moving Average is calculated to be 60.82%.
Shares Statistics:
TSHA traded an average of 3.84M shares per day over the past three months and 2585140 shares per day over the past ten days. A total of 273.92M shares are outstanding, with a floating share count of 223.27M. Insiders hold about 18.49% of the company’s shares, while institutions hold 89.58% stake in the company. Shares short for TSHA as of 1765756800 were 48586771 with a Short Ratio of 12.64, compared to 1763078400 on 48083858. Therefore, it implies a Short% of Shares Outstanding of 48586771 and a Short% of Float of 19.81.
Earnings Estimates
As of right now, 5 analysts gave their recommendation on the stock of the company. The consensus estimate for the next quarter is -$0.1, with high estimates of -$0.07 and low estimates of -$0.12.
Analysts are recommending an EPS of between -$0.24 and -$0.38 for the fiscal current year, implying an average EPS of -$0.34. EPS for the following year is -$0.44, with 5.0 analysts recommending between -$0.29 and -$0.54.
Revenue Estimates
A total of 13 analysts have provided revenue estimates for TSHA’s current fiscal year. The highest revenue estimate was $15M, while the lowest revenue estimate was $4M, resulting in an average revenue estimate of $6.3M. In the same quarter a year ago, actual revenue was $8.33M
